Results 181 to 190 of about 3,092 (212)

Retrospective survey to evaluate the safety and efficacy of Japanese botulinum antitoxin therapy in Japan

Toxicon, 2016
Japanese botulinum antitoxins have been used for more than 50 years; however, their safety and therapeutic efficacy are not clear. In order to analyze the available data on botulinum antitoxin therapy in Japan, we surveyed published reports about botulism cases in which botulinum antitoxins were used, and retrospectively analyzed the safety and ...
Masaaki Iwaki, Akihiro Ginnaga, Motohide Takahashi, Yasushi Torii, Keita Mottate, Akira Horita, Hiroyuki Yokote, Yoshinobu Miyatsu, Shigemi Mori, Shunji Kozaki   +9 more
openaire   +4 more sources

Preparation, measurement and possible use of human antitoxin againstCl. botulinum A, B, and E toxins

Medical Microbiology and Immunology, 1975
Human antibodies against botulinum toxins A, B, and E have been raised by repeated injections of pentavalent toxoid in a healthy volunteer. The final titer was 3.2 U anti-A, 0.4 U anti-B, and 2.5 U anti-E/ml. In mice, the efficacy of the antitoxin decreases with the time between poisoning and application of the antiserum.
Sandor Bernáth, Ernst Habermann
openaire   +4 more sources

Differences in immunological responses of polyclonal botulinum A1 and A2 antitoxin against A1 and A2 toxin

Toxicon, 2013
Botulinum type A antitoxin in standard and therapeutic preparation is a polyclonal antibody purified from immunized sera with subtype A1 toxin. To investigate the difference between immunological responses of antitoxin against toxin among different subtypes, we examined the response of polyclonal A1 and A2 antitoxins with A1 and A2 toxins. In the mouse
Motohide Takahashi, Akihiro Ginnaga, Tomoko Kohda, Yasushi Torii, Miho Shinmura, Shunji Kozaki   +5 more
openaire   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Iatrogenic Botulism: A Case Treated With Botulinum Antitoxin

Clinical Neuropharmacology, 2022
Objective Botulinum toxin type A is widely used for the treatment of spasticity, focal dystonia, hemifacial spasm, hyperhidrosis, strabismus, chronic migraine, and also cosmetic purposes. Therapeutic use is commonly effective and safe.
Ozge Gonul Oner, Hasan Can Gudek, Ozdem Erturk Cetin, Serkan Demir   +3 more
openaire   +2 more sources

Infant botulism in Australia: availability of human botulinum antitoxin for treatment

Medical Journal of Australia, 2010
We report the first Australian case of treatment of infant botulism with a human botulinum antitoxin developed in the United States by the California Department of Public Health. Our patient's clinical improvement was rapid, and although the product is expensive, cost-analysis supports the economical viability of its use.
May, M. L. A., Corkeron, M. A., Stretton, M.   +2 more
openaire   +3 more sources

BOTULINUM ANTITOXIN AS A THERAPEUTIC AGENT IN MONKEYS WITH EXPERIMENTAL BOTULISM [PDF]

, 1965
Abstract : Antitoxin administered soon after the appearance of the first toxic signs in monkeys given 2.5 to 5.0 LD50's of botulinum toxin resulted in complete recovery in 11 out of 15 animals when liquid food and fluids were forced during the period of aphagia. When no supportive treatment was applied, only one out of six survived.
James W. Crook, Paul Cresthull, Michael J. House, Fred W. Oberst   +3 more
openaire   +1 more source

An in vitro cell-based potency assay for pharmaceutical type A botulinum antitoxins

Vaccine, 2017
Botulism therapy relies on passive immunization with antitoxin. The mouse neutralization test is the only pharmacopeia assay to measure the potency of antitoxin preparations. Herein, we present an in vitro cell-based assay for the measurement of pharmaceutical type A antitoxin potency. Accuracy, reproducibility and compatibility with the mouse bioassay
Lilach Levin, Eyal Epstein, Ronit Rosenfeld, Alon Ben David, Amram Torgeman, Meni Girshengorn, Eran Diamant, Ran Zichel, Ohad Mazor   +8 more
openaire   +3 more sources

Development of an Avian Antitoxin to Type A Botulinum Neurotoxin

1993
Most commercially available antitoxins and antivenoms are raised in horses and purified by bulk fractionation techniques. These preparations frequently elicit deleterious side effects that compromise their efficacy and the treatment of intoxication or envenomation.
B. S. Thalley, B. R. DasGupta, S. B. Carroll, D. C. Stafford, M. B. van Boldrik, W. Tepp   +5 more
openaire   +2 more sources

Anti‐immunoglobulin Responses to IgG, F(ab′)₂, and Fab Botulinum Antitoxins in Mice

Immunopharmacology and Immunotoxicology, 2003
Side effects to botulinum antitoxins, including anaphylaxis and serum sickness, are common. This is due to the immunogenicity of the antitoxin, which can be measured by the production of anti-immunoglobulin antibodies. An ideal botulinum antitoxin would elicit a minimal production of anti-immunoglobulin antibodies from a patient, aiding its safety.
Shelagh Veall, Jane L Holley, Richard J Bedford, Carl Nicholas Mayers   +3 more
openaire   +2 more sources

Development and preclinical evaluation of a new F(ab′)2 antitoxin against botulinum neurotoxin serotype A

Biochimie, 2010
Concern about the malicious applications of botulinum neurotoxin has highlighted the need for a new generation of safe and highly potent antitoxins. In this study, we developed and evaluated the preclinical pharmacology and safety of a new F(ab')₂ antitoxin against botulinum neurotoxin serotype A (BoNT/A).
Pei-Tang Huang, Zhi-Wei Sun, Yun-Zhou Yu, Yun Du, Xiao-Wei Zhou, Rui-Lin Wang, Shuang Wang, Shu-Ming Zhang, Heng-Qi Zhu, Wen-Bing Wang, Jianbo Lin, Wei-Yuan Yu   +11 more
openaire   +3 more sources